Generate Biomedicines (NASDAQ:GENB) Shares Gap Up - Here's Why

Key Points

• Generate Biomedicines shares jumped 7%: GENB opened at $17.11 versus a prior close of $16.14, with the stock later trading near $16.76.
• Analyst sentiment remains mixed but leans positive: Six analysts rate the stock Buy, compared with one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $25.40.
• The company missed quarterly earnings expectations: Generate Biomedicines reported a loss of $0.52 per share versus the $0.48 consensus estimate, while revenue totaled $6.31 million; analysts project a full-year loss of $2.29 per share.

Shares of Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $16.14, but opened at $17.11. Generate Biomedicines shares last traded at $16.7630, with a volume of 574,702 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GENB. Weiss Ratings began coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They set a "sell (d)" rating for the company. HC Wainwright boosted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Thursday, May 14th. Finally, Wall Street Zen cut shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $25.40.

Generate Biomedicines Trading Up 7.0%

The company has a fifty day simple moving average of $15.23. The firm has a market cap of $2.22 billion and a P/E ratio of -10.78.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. As a group, sell-side analysts forecast that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Generate Biomedicines

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new stake in shares of Generate Biomedicines during the second quarter valued at approximately $96,000. Susquehanna International Group LLP bought a new position in Generate Biomedicines in the 2nd quarter worth approximately $196,000. AXQ Capital LP bought a new position in Generate Biomedicines in the 2nd quarter worth approximately $218,000. Bank of New York Mellon Corp acquired a new position in Generate Biomedicines during the 2nd quarter worth $967,000. Finally, Braidwell LP acquired a new position in Generate Biomedicines during the 2nd quarter worth $55,398,000.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source